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Insulin-like growth factor-l (IGF-I) is emerging as a powerful 
neuroprotective molecule that is strongly induced in the 
central nervous system after different insults. We con­
structed a recombinant adenoviral vector (RAd-IGFI) harbor­
ing the gene for rat IGF-I and used it to implement IGF-I gene 
therapy in the hypothalamus of senile female rats, which 
display hypothalamic dopaminergic (DA) neurodegeneration 
and as a consequence, chronic hyperprolactinemia. Resto­
rative IGF-I gene therapy was implemented in young (5 
months) and senile (28 months) female rats, which received 
a single intrahypothalamic injection of3x 10r> plaque-forming 
units of RAd-ftgal (a control adenoviral vector expressing 
p-galactosidase) or RAd-IGFI and were killed 17 days post­
injection. In the young animals, neither vector modified 
serum prolactin levels, but in the RAd-IGFI-injected senile 
rats a nearly full reversion of their hyperprolactinemic status 
was recorded. Morphometric analysis revealed a significant 
increase in the total number of tyrosine hydroxylase-positive 
cells in the hypothalamus of experimental as compared with 
control senile animals (5874±486 and 3390±498, respec­
tively). Our results indicate that IGF-I gene therapy in senile 
female rats is highly effective for restoring their hypothalamic 
DA dysfunction and thus reversing their chronic hyper­
prolactinemia.
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Introduction
Aging is associated with a progressive increase in the 
incidence of neurodegenerative diseases in both labora­
tory animals and humans. In the central nervous system 
(CNS), dopaminergic (DA) neurons are among the cells 
most susceptible to the deleterious effects of age. Thus 
in humans, Parkinson's disease, a degeneration of nigro- 
striatal DA neurons, which affects 0.1-0.3% of the 
population, is the most conspicuous reflection of the 
vulnerability of DA neurons to age.1 In rats, aging brings 
about a progressive dysfunction and loss of another 
group of central DA neurons namely, the hypothalamic 
tuberoinfundibular dopaminergic (TIDA) neurons, 
which are involved in the tonic inhibitory control of 
prolactin (PRL) secretion and lactotrophic cell pro­
liferation in the adenohypophysis.2 Degeneration and 
loss of TIDA neurons during normal aging are asso­
ciated, in the female rat, with progressive hyperprolacti­
nemia3 and the development of pituitary prolactinomas.4 
This neuroendocrine pathology of aging female rats 
provides a convenient animal model to assess the
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efficacy of therapeutic strategies aimed at protecting 
central DA neurons. Interestingly, Parkinsonian patients 
usually reveal functional alterations in the hypothalamo- 
PRL axis.5
Neurotrophic factors that prevent the degeneration 
and enhance the recovery of remaining DA neurons are 
of clinical interest. Among them, insulin-like growth 
factor-I (IGF-I) is emerging as a powerful neuroprotec­
tive molecule, which is strongly induced in the CNS after 
different insults such as ischemia,6 cortical injury78 and 
injury of the spinal cord.9 In situations involving 
cytotoxic damage in the hippocampus, the microglia of 
this region dramatically increase the production of IGF-I- 
and IGF-I-binding protein 2, which suggests a neuropro­
tective role of these molecules in the CNS.10 Furthermore, 
IGF-I has been reported to protect hippocampal neurons 
from the toxic effects of amyloid peptides.11 Interestingly, 
IGF-I treatment of mice overexpressing a mutant A// 
amyloid peptide markedly reduced their brain burden of 
A// amyloid.12 In vitro studies have shown that IGF-I 
increases cell survival in primary hypothalamic cell 
cultures13 and stimulates differentiation of rat mescence- 
phalic DA neurons.14 A protective effect of IGF-I has 
been reported in immortalized hypothalamic cells 
exposed to reduced glutathione-depleting agents,15 in 
human DA cell cultures exposed to the toxin salsolinol16 
and in human and rodent neuronal cultures exposed to 
toxic doses of DA.17
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Prompted by the above evidence, we constructed 
an adenoviral vector harboring the gene for rat IGF-I 
and used it to implement IGF-I gene therapy in the 
hypothalamus of hyperprolactinemic senile female rats. 
The present report documents the effectiveness of this 
therapeutic strategy in reversing hyperprolactinemia and 
increasing DA function in the hypothalamus of the 
senescent animals.
In vivo hypothalamic IGF-I gene transfer
Intrahypothalamic injection of RAd-/<gal or RAd-IGH in 
young (5 months) female rats followed by killing of the 
animals at different times post-injection, showed that 
RAd-IGFI-injected animals overexpressed IGF-I in the 
hypothalamus for about 50 days. At post-injection day 
70, hypothalamic IGF-I content was not significantly 
different between RAd-/igal- and RAd-IGFI-injected rats 
(Figure 2).
Results
In vitro IGF-I gene transfer
Recombinant adenoviral vector harboring the gene for 
rat IGF-I (RAd-IGH) induced a significant overexpres­
sion of IGF-I in both B92 glial and N2a neuronal cells 
as compared with their corresponding counterparts 
incubated with RAd-/<gal (Figure 1). In the glial cells, 
RAd-IGFI induced a marked increase in the release 
of IGF-I. Both cell types produced comparable levels 
of IGF-I when incubated for 3 days with either RAd-/igal 
or medium alone (data not shown). No cytopathic 
effects were detected in either B92 or N2a cells at the 
vector concentrations used.
Figure 1 Intracellular and secreted levels of IGF-I in RAd-IGFI- 
transduced neuronal and glial cells. N2a mouse neuroblastoma cells 
(upper panel) and B92 rat glial cells (lower panel) were incubated 
for 3 days with either RAd-/>gal (open columns) or RAd-IGFI (solid 
columns). Supernatants were collected, cells scraped from the well's 
bottom and resuspended in medium (see Materials and methods 
section for further details). Total IGF-I was assayed in supernatants 
and lysates and the peptide concentration referred to the original 
volume of medium per well. Bars on columns represent s.e.m. 
(n = 5). *P<0.05; **P<0.01.
IGF-I gene therapy in the hypothalamus of senile 
female rats
Seventeen-day IGF-I gene therapy was implemented 
according to the experimental design described in 
Materials and methods (Figure 3).
Enzymohistochemical assessment of the hypothala­
mus from young and senescent female rats, 17 days after 
RAd-/igal injection, revealed a widespread distribution 
of X-gal-positive cells in both the arcuate-periventricular 
(ARC-PeV) and the paraventricular (PaV) regions (Figure 
4). At the end of the treatment, total IGF-I content in the 
medial basal hypothalamus (MBH) of senescent animals 
was higher in the RAd-IGFI- than in the RAd-/<gal- 
injected group (Figure 4, lower inset).
In the young animals, serum PRL profiles were not 
affected by hypothalamic injection of either RAd-/<gal or 
RAd-IGFI (Figure 5, lower panel). In contrast, treatment 
with RAd-IGFI but not with RAd-/<gal induced a marked 
fall of serum PRL levels in the senescent female rats, 
thus reversing the chronic hyperprolactinemia typically 
present in aged female rats (Figure 5, upper panel). As 
expected, there was a slight age-related increase in serum 
estradiol, but the RAd-IGFI treatment did not affect the 
circulating levels of this steroid (Figure 5, inset).
Quantitative immunohistochemical assessment revea­
led that in the senile but not in the young female rats, 
IGF-I gene therapy induced an increase in the number 
of hypothalamic tyrosine hydroxylase positive (TH+)
Days post-vector injection
Figure 2 Assessment of the length of IGF-I expression in the Arc- 
PeV region of young rats intrahypothalamically injected with RAd- 
IGFI. On experimental day 0, animals received a bilateral stereotaxic 
injection of either RAd-jlgal (solid symbols) or RAd-IGFI (open 
symbols) in the ARC-PeV hypothalamic region. At the indicated 
times, groups of 3-4 rats were killed, the ARC-PeV-median 
eminence region removed by micropunch and assayed for IGF-I. 
Bars on columns represent s.e.m. *P<0.05; **P<0.01
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Figure 3 Experimental design for IGF-I gene therapy in the hypothalamus of female rats. Two identical but independent experiments were 
performed using this design. Animals were bled at experimental days —3, 3, 7, 10, 14 and 17, taking 0.3-0.4 ml blood from the tail veins in 
each sampling. RAd-/Jgal (controls) or RAd-IGFI (experimental) were stereotaxically injected in the hypothalamus of young and senile female 
rats on experimental day 0. See Results for further details.
Figure 4 Expression of /’-gal in the hypothalamus of young and senile female rats 17 days after RAd-/Jgal injection. Control rats were killed 
17 days after receiving a single bilateral intrahypothalamic injection of RAd-/Jgal. Expression of /3-gal in hypothalamic sections was detected 
by the X-gal technique (positive cells stained in blue). The main panel shows /?-gal expression in the medial hypothalamus of a representative 
senile female rat. High frequency of transduced cells is observed along the tracks left by the needle during vector injection (arrows). Left and 
right upper insets show /¡-gal expression in the PaV region of a young and senile control animal, respectively. The lower inset on the left 
shows IGF-I content in the MBH of RAd-/Jgal- and RAd-IGH-treated senile rats, 17 days after the corresponding vector injection. 
*A significant (P<0.05) difference between the two groups (N per group = 4). For further technical details see Materials and methods. 
ARC: arcuate hypothalamic nucleus; PeV: periventricular hypothalamic nucleus; PaV: paraventricular hypothalamic nucleus; 3V: third 
ventricle. Objectives x 1.5 and x 10 for main panel and insets, respectively.
neurons as compared with the R Ad-/¡gal-treated counter­
parts (Figure 6). This change was significant in the PaV 
nucleus (P<0.05) and near significant in the ARC-PeV 
region (P = 0.07). Morphometric analysis of the effect of 
IGF-I gene therapy on other morphologic characteristics 
of hypothalamic DA neurons including cell perimeter, 
cell area and roundness revealed that the treatment 
induced no significant changes in the young rats and 
only minor changes in the senile animals (data not 
shown). Although the number of DA hypothalamic 
neurons was comparable between young and senile 
control rats, TH immunostaining was generally fainter in 
the latter. This was quantitatively assessed by morpho­
metrically estimating the average optical density per TH 
cell in the different experimental groups (data not 
shown). This loss of immunoreactivity in the senile
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Figure 5 Effect of IGF-I gene therapy on serum PRL levels in 
young and senile female rats. The panels show the effect of 
intrahypothalamic injection of RAd-/lgal or RAd-IGFI on serum 
PRL profiles during a 17-day-long post-injection period. The lower 
and upper panels correspond to young (5 months) and senile (28 
months) animals, respectively. The columns in light gray (experi­
mental day —3) indicate pre-injection PRL levels. Notice that at pre­
injection time all senile female rats were hyperprolactinemic as 
compared to reference values from intact young female rats (dotted 
line). The number of animals in the young control, young 
experimental, senile control and senile experimental groups were 
10, 11, 9 and 12, respectively. Bars over columns represent s.e.m. 
values. The significance of differences between post-injection versus 
the corresponding pre-injection PRL value is indicated by 
* (P<0.05) or ** (P<0.01) over columns. Inset shows 17/1-estradiol 
levels in the serum of RAd-/lgal- (open columns) and RAd-IGFI- 
treated rats of both age groups at experimental day 17. Y: young; S: 
senile. Asterisk (*) on column indicates a significant difference of 
senile controls versus young controls. N values for estradiol data are 
4, 5, 5 and 4, for Y-/lgal, Y-IGFI, S-/lgal and S-IGFI, respectively.
animals was partly reversed by IGF-I gene therapy 
(Figure 7).
Discussion
A number of in vivo models have been developed for the 
study of the pathophysiology of Parkinson's disease as 
well as for the assessment of new therapeutic strategies 
for this devastating disease. They include the use of
Figure 6 Effect of IGF-I gene therapy on DA neuron number in 
the hypothalamus of young and senile rats. The graphs show 
the quantitation of TH+ neurons in the ARC-PeV region, and in 
the PaV nucleus as well as the total TH+ neuron number in the 
hypothalamus. Animals were killed 17 days after the corresponding 
vector injection in the hypothalamus. Open and solid columns 
correspond to animals injected with RAd-/lgal or RAd-IGFI, 
respectively. TH+ neuron counting was performed both manually 
and automatically using an appropriate image analysis software 
(see Materials and methods for further details). Bars over columns 
represent s.e.m. values G\'— 4). Significant differences between the 
RAd-/lgal- and RAd-IGFI-injected groups for each pair of columns 
are indicated by asterisks (*) over the solid column. *P<0.05; 
**P<0.01.
neurotoxins to lesion nigral DA neurons in primates 
and rodents and the generation of transgenic models 
overexpressing a-synuclein.18 Although each of these 
paradigms has provided useful information for the 
understanding of Parkinson's disease, they share a signi­
ficant limitation namely, that the neurological lesions 
they study are caused by experimental manipulations 
rather than by aging, the only unequivocal risk factor for 
Parkinson's disease.19'20 In this context, the aging female 
rat emerges as a unique model of spontaneous and 
progressive age-related DA dysfunction. Besides, the 
functional status of TIDA neurons can be readily 
monitored in the animals by measuring circulating PRL 
levels. The advantages of the neuroendocrine system for 
the evaluation of gene therapy strategies in the CNS has 
been already demonstrated in the Brattleboro rat, a 
mutant lacking arginine-vasopressin (AVP), which is 
used as a model of diabetes insipidus.21 When an 
adenoviral vector encoding the rat AVP cDNA was 
stereotaxically injected into the supraoptic nucleus of 
Brattleboro rats, a substantial expression of AVP in 
magnocellular cells as well as the presence of immuno- 
histochemically detectable AVP in their axons projecting 
to the posterior pituitary was detected. Measurement of 
urine output and urine osmolality showed that the 
symptoms of diabetes insipidus in the Brattleboro rats
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Figure 7 Effect of IGF-I gene therapy on the DA neurons of the ARC-PeV hypothalamic region in young and senile female rats. The 
representative coronal hypothalamic sections shown pass through the medial hypothalamus and were immunolabeled with a monoclonal 
anti-rat TH antibody. Animals were killed 17 days after the corresponding vector injection in the hypothalamus. The upper panels correspond 
to young animals injected with either RAd-/lgal (left) or RAd-IGFI (right). The lower panels show the corresponding senile counterparts. 
Objective x 20.
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were significantly reduced for up to 4 months after 
injection of the viral vector.22
The present study is, to our knowledge, the first 
attempt to use IGF-I gene therapy for the restoration of 
DA neuron function in aged rats. The RAd-IGFI vector 
constructed for this purpose proved to be effective in 
inducing IGF-I overexpression in glial and neuronal cell 
lines as well as in the hypothalamus of young and old 
rats. The length of expression (50 days) of transgenic 
IGF-I achieved in vivo with our adenoviral vector was 
shorter than that reported for adenovirally delivered 
AVP (4 months) in the above-mentioned studies in the 
hypothalamus of Brattleboro rats.22 This may be due to 
the fact that the two transgenes were driven by different 
promoters. Morphologic assessment of RAd-/)gal- 
injected rats 17 days post-surgery revealed a widespread 
distribution of transduced cells in the medial hypo­
thalamus, which suggests that transgenic IGF-I also 
reached the PaV and ARC-PeVregions. RAd-/)gal has not 
the same backbone as RAd-IGFI, but we chose to use it 
despite this fact because its performance in the hypo­
thalamus is well characterized in our laboratory.
The DA neurons of the rat hypothalamus are grouped 
into two main areas, A12 and A14,23-24 with the DA 
perikarya of the A12 area being located in the ARC 
nucleus and in the periarcuate region.25 The A14 DA 
neurons are mainly located within the PaV and PeV 
nuclei, with a few scattered DA neurons in the anterior 
ventromedial hypothalamic area.25'26 The A12 area and 
its corresponding axon terminals constitute the TIDA 
system, whereas the A14 area and its fibers are known as 
the periventricular dopaminergic system. Both systems 
regulate PRL secretion by exerting a tonic inhibitory 
control on both PRL secretion and lactotroph pro­
liferation.27 In early studies, TIDA neuron function was 
reported to decline during aging in rats, with a marked 
reduction in hypothalamic, median eminence and 
neurointermediate lobe DA content in old (24-26 
months) as compared with young (4 months) rats.28 
More significant, the rate of DA secretion into the 
hypophysial portal blood of aged (20-26 months) male 
and female rats was found to decline drastically when 
compared with young (2-4 months) counterparts.29'30 
Although the above age-related alterations in hypotha­
lamic DA secretion were ascribed to a functional decline 
of TIDA neurons rather than to TIDA neuron loss,31 more 
recent work in very old female rats (32 months) showed 
that at extreme ages, DA neuron loss occurs in the rat 
hypothalamus.32 In the present study, comparison 
of total hypothalamic DA neuron number in 5- versus 
28-month-old control female rats (3516 versus 3390, 
respectively) shows a slight nonsignificant decline, 
which is in acceptable agreement with the above reports. 
The marked hyperprolactinemia of our senile animals in 
the face of minimal TIDA neuron loss, supports the 
hypothesis proposed by others namely, that in the aging 
female rat most TIDA neurons survive but become 
progressively dysfunctional.31 In line with this idea, the 
poor TH immunoreactivity of hypothalamic sections 
from senile control rats suggests low levels of neuronal 
TH. In this context, the marked reversion of chronic 
hyperprolactinemia effected by RAd-IGFI but not RAd- 
/)ga 1 treatment in the senile female rats, strongly suggests 
that overexpression of IGF-I in the hypothalamus of the
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aged animals restored DA neuron function and/or 
number (see below).
Although we are unaware of studies on the protective 
activity of IGF-I on adult hypothalamic DA neurons, our 
results are not unexpected in view of the well-established 
neuroprotective activity of IGF-I in other brain regions. 
In a rat model of cerebellar ataxia (induced by
3- acetylpyridine (AC)), subcutaneous or intracerebroven- 
tricular administration of IGF-I restored motor coordina­
tion and partially rescued inferior olive neurons from the 
toxic effect of AC.33 Two- and 4-week continuous 
infusion of IGF-I in the lateral ventricle partially restored 
reference and working memory in 32- as compared to
4- month-old male rats.34 Also, the neuroprotective effect 
of physical exercise in rodent models of ataxia, domoic 
acid-mediated hippocampal damage and inherited 
Purkinje cell degeneration (ped mouse model) was 
reported to be mediated by circulating IGF-I.35
Our morphometric data show an increase in TH+ 
neurons in the hypothalamus of senile rats treated with 
RAd-IGFI. This increase could be accounted for by 
a trophic effect of transgenic IGF-I on pre-existing 
dysfunctional DA neurons expressing low levels of TH 
(putative TH— DA neurons), which would be rendered 
TH+ by the treatment. Nevertheless, our findings are 
also consistent with a neurogenic effect of IGF-I in 
the hypothalamus of the senile animals. Although the 
assessment of neurogenesis was beyond the scope of 
the present study, this possibility should be mentioned. 
In the hippocampus of adult rats, IGF-I has been repor­
ted to selectively induce neurogenesis.36 Furthermore, 
the exercise-induced increase in the number of hippo­
campal neurons has been shown to be mediated by 
circulating IGF-I.37 Interestingly, it has been recently 
reported that neural progenitor cells exist in the epen­
dymal layer of the adult rat's third ventricle and that 
they may migrate and differentiate into hypothalamic 
neurons.38
The present study describes the implementation of 
restorative gene therapy in an unexplored animal model 
of age-related central DA neuron degeneration. Using 
this paradigm, we demonstrate that IGF-I gene therapy 
in the hypothalamus of hyperprolactinemic senile female 
rats is highly effective in reversing TIDA dysfunction. 
Future studies exploring the restorative ability of IGF-I 
in the substantia nigra of Parkinson's disease models as 
well as the possible neurogenic activity of IGF-I in the 
hypothalamus and substantia nigra of aged rats may 
prove to be highly rewarding.
Materials and methods
Adenoviral vectors
RAd-IGFI. A RAd vector harboring the rat IGF-I gene 
(kindly donated by Dr Peter Rotwein, Oregon Health 
Sciences University) was constructed by a variant of the 
two-plasmid method39 employing the AdMax plasmid 
kit (Microbix, ON, Canada). Briefly, the cDNA coding for 
rat IGF-I gene (obtained from the mRNA for the IGF-Ib 
precursor form)40 was excised from plasmid pBluescript 
KS, subcloned in pCA14 and inserted in the multiple 
cloning site (MCS) of shuttle pDC515 (one of the 
plasmids of the kit), which contains an expression 
cassette consisting of the mouse cytomegalovirus pro­
moter and the simian virus 40 polyadenylation signal, 
immediately upstream and downstream to the MCS, 
respectively. Downstream this cassette, pDC515 also 
contains an frt recognition site for the yeast FLP 
recombinase. The second plasmid of the kit, the genomic 
plasmid pBHGfrt(del)El,3 FLP, consists of the entire 
genome of adenovirus 5 (Ad5), containing deletions in 
the regions El and E3. Upstream to the El deletion, 
pBHGfrt(del)El,3 FLP contains an expression cassette for 
the gene for yeast FLP recombinase and immediately 
downstream to the El deletion, there is an frt recognition 
site. Both plasmids were co-transfected in HEK293 
cells, a line stably transfected with a portion of the Ad5 
El genomic region. In co-transfected HEK293 cells, FLP 
recombinase is readily expressed and efficiently cata­
lyzes the site-directed recombination of the expression 
cassette of pDC515 into pBHGfrt(del)El,3 FLP, thus 
generating the genome of the desired recombinant 
adenoviral vector, RAd-IGFI. The newly generated RAd 
was rescued from HEK293 cell lysates and plaque 
purified. It was further purified by ultracentrifugation 
in a CsCl gradient. Final virus stocks were titrated by 
a serial dilution plaque assay.
RAd-figal. This RAd was kindly provided by Dr 
Michel Perricaudet, Institut Gustave Roussy, CNRS, 
Paris. In this vector, the El genomic region has been 
replaced by an expression cassette containing the 
Escherichia coli lac Z reporter gene under the control of 
the Rous sarcoma virus long terminal repeat. The vector 
was expanded in 293 cells and purified and titrated as 
indicated for RAd-IGFI.
In vitro studies
Cell cultures. The B92 rat glial cell line and the N2a 
mouse neuroblastoma cell line were used to test the 
effectiveness of RAd-IGFI in vitro. Cells were grown in 
Eagle's minimum essential medium (MEM), 16.8 mM 
Hepes buffer (pH 7.0), 2 mM glutamine, 0.1 mM non- 
essential amino acids, 20 mg/1 penicillin/streptomycin, 
3.3 mg/1 amphotericin B, 2.2 mg/1 NaHCO3 and 10% 
(v/v) fetal bovine serum. They were grown at 37°C in a 
humidified atmosphere of 95% air-5% CO2. Cells were 
fed every 3-4 days and split when confluent.
Cell transduction protocol. Cells were plated on six- 
well plates. When a density of 1.5-2.0 x 105 cells/well 
was reached, the medium was replaced by 1 ml fresh 
medium containing 2 x 108 plaque-forming units (p.f.u./ 
ml) RAd-/igal or RAd-IGFI. After 3 days, cell super­
natants were collected by gentle aspiration, 1 ml MEM 
per well was added to cells and they were scrapped 
off. Cell suspensions were freeze-thawed three times, 
centrifuged at 1000 g for 10 min and lysates collected. 
Total IGF-I was measured in both supernatants and 
lysates.
Animals
Young (Y, 5 months) and senescent (S, 28-31 months) 
female Sprague-Dawley rats, raised in our gerontologi­
cal rat colony, were used. Animals were housed in 
a temperature-controlled room (22 + 2°C) on a 14:10 h 
light/dark cycle. Food and water were available ad 
libitum. In our gerontological rat colony, the average 50% 
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survival time for female rats, studied in groups of 50-60 
animals, is 33 months (range 32-34 months). All 
experiments with animals were performed according to 
the Guidelines on the Use of Animals in Neuroscience 
Research (the Society of Neuroscience) using Institu­
tional Animal Care and Use Committee (IACUC) 
approved procedures (approval date 6 January 2004) 
and Animal Welfare Guidelines of NIH (INIBIOLP's 
Animal Welfare Assurance No. A5647-01).
Experimental design for in vivo IGF-I gene therapy
Young and senescent female rats were allotted to a 
control or experimental group, thus forming four groups: 
young control (Y-/igal), young experimental (Y-IGFI), 
senescent control (S-/7gal) and senescent experimental 
(S-IGF1). Beginning at experimental day —3, a small 
blood sample (0.3-0.4 ml) was taken from the tail veins 
of all rats at the indicated times (Figure 3). Serum was 
obtained and kept at —20°C for hormone assay.
On Experimental day 0, control and experimental 
animals received bilateral 1.5-/(1 intrahypothalamic injec­
tions containing 3 x 109 p.f.u. RAd-Jigal or RAd-IGFI, 
respectively. For this purpose, rats were anesthetized 
by injection of ketamine hydrochloride (40 mg/kg, intra­
peritoneal) and xylazine (8 mg/kg, intramuscular), and 
placed in a stereotaxic frame. In order to access the ARC- 
PeV region, the tip of a 26 G needle fitted to a 10 /zl 
syringe was brought to the following coordinates relative 
to the bregma: 3.0 mm posterior, 10.0 mm ventral and 
0.6 mm right and left.41
On experimental day 17, part of the rats from the 
four groups were killed by rapid decapitation, the brain 
was rapidly removed from the cranium, placed on a dry 
ice block and the MBH dissected and homogenized 
for determination of IGF-I content (in some animals, the 
ARC-PeV-median eminence region was obtained by 
micropunch). The remaining animals were placed under 
deep anesthesia and perfused with phosphate-buffered 
formaldehyde 4% (pH 7.4) fixative. Each brain was 
removed and trimmed down to a block containing the 
whole hypothalamus. The block was then serially 
cut into coronal sections 40 /zm thick on a freezing 
microtome.
Immunohistochemistry
In each block, one every six serial sections was selected 
in order to obtain a set of non-contiguous serial sections 
spanning the whole hypothalamus. Typically, a whole 
hypothalamus comprised about 48 coronal sections, thus 
yielding six sets of eight non-contiguous serial sections. 
For counting purposes, each set was considered as 
representative of the whole hypothalamus. For each 
animal, one set of sections was immunohistochemically 
processed using an anti-TH monoclonal antibody 
(Calbiochem Inc., La Jolla, CA, USA). For detection, the 
Vectastain Universal ABC kit (Vector Laboratories Inc., 
Burlingame, CA, USA) employing 3,3-diamino benzidine 
tretrahydrochloride as chromogen was used. Sections 
were dehydrated, mounted and used for image analysis.
Image analysis
Stereological quantitation of hypothalamic TH neurons 
was performed as previously described, with minor 
modifications.32 Briefly, images of the DA areas of 
hypothalamic sections were captured using an Olympus
DP70 digital camera attached to an Olympus BX51 
microscope (Tokyo, Japan). Digital images were analyzed 
using the ImagePro Plus (IPP) v5.1 image analysis 
software (Media Cybernetics, Silver Spring, MA, USA). 
In order to avoid double counting errors, only TH 
neurons showing clearly shaped nuclei were counted. 
The total number (N) of TH neurons per nucleus was 
estimated using the following equation:
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n.s
Where, d = length (mm) of the rostrocaudal axis of the 
hypothalamus being assessed; n = number of slices 
assessed per hypothalamus; s = thickness of sections 
(40/zm); x = number of TH neurons counted per slice 
assessed.
Enzymohistochemistry
In the animals injected with RAcL/lgal, the hypothalamic 
sections were submitted to enzymohistochemistry for 
E. coli /Lgalactosidase. Sections were incubated overnight 
in 0.01% 5-bromo-4-chloro-3-indolyl-b-D-galactopyrano- 
side (X-gal; Calbiochem, San Diego, CA, USA), 5 mM 
K3Fe(CN)6-K4Fe(CN)6, 2 mM MgCl2 solution, dehydrated 
and mounted for light microscopy assessment.
Hormone assays
For all hormones, serum or brain samples were assayed 
in duplicate. Serum PRL was measured by a specific 
radioimmunoassay (RIA) following a protocol pre­
viously described4 and using the rat materials provided 
by Dr AF Parlow, Pituitary Hormones and Antisera 
Center, Harbor-UCLA Medical Center, Torrance, CA, 
USA. Serum PRL was expressed in terms of NHPP rPRL 
RP-3.
For IGF-I RIA, cell culture samples and hypothalamic 
specimens were subjected to acid-ethanol cryoprecipita­
tion as described by Breier et old2 For B92 and N2a cells, 
150 /zl lysates or supernatants prepared as indicated 
above, were submitted to acid-ethanol extraction. The 
MBH and ARC-PeV-median eminence regions were 
dissected and homogenized in 150 /zl Tris-HCl (60 mM), 
ethylenediaminetetraacetic acid (1 mM) with protease 
inhibitors, pH 6.8. Homogenates were centrifuged at 
800 g, and 90 /zl supernatants were subjected to acid- 
ethanol extraction. IGF-I was determined as previously 
described43 using antibody (UB2-495) provided by Drs L 
Underwood and JJ Van Wyk, and distributed by the 
Hormone Distribution Program of the NIDDK and Dr 
AF Parlow. Recombinant human IGF-I (Chiron Corp., 
Emeryville, CA, USA) was used as radioligand and 
unlabeled ligand.
Serum 17/LestradioI was measured by RIA using a 
commercial solid phase kit (Coat-A-Count, DPC, Los 
Angeles, CA, USA) and following the manufacturer's 
instructions.
Statistical analysis
The f-test or the analysis of variance was used, as 
appropriate, to evaluate group differences. Tukey's 
method was chosen as a post hoc test. Significant differen­
ces between rat groups for each hypothalamic area were 
defined as those with a P<0.05. Highly significant 
differences were defined as those with a P-value <0.01.
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